908 Devices (NASDAQ:MASS) Rating Increased to Hold at Wall Street Zen

908 Devices (NASDAQ:MASS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday.

MASS has been the topic of a number of other reports. Leerink Partners raised shares of 908 Devices from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a research note on Tuesday, August 5th. Leerink Partnrs raised shares of 908 Devices from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a research note on Saturday, August 30th. One analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. Based on data from MarketBeat, 908 Devices currently has an average rating of “Buy” and a consensus target price of $8.00.

908 Devices Trading Down 2.1%

908 Devices stock opened at $5.60 on Monday. 908 Devices has a 12-month low of $1.81 and a 12-month high of $8.06. The stock has a market cap of $200.82 million, a P/E ratio of -10.37 and a beta of 0.37. The company has a 50-day moving average price of $6.46 and a 200 day moving average price of $5.61.

908 Devices (NASDAQ:MASS) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). 908 Devices had a negative return on equity of 24.30% and a negative net margin of 30.54%.The firm had revenue of $4.70 million for the quarter, compared to analyst estimates of $12.17 million. 908 Devices has set its FY 2025 guidance at EPS. As a group, analysts forecast that 908 Devices will post -1.99 EPS for the current year.

Insider Buying and Selling

In other 908 Devices news, insider Michael S. Turner sold 7,148 shares of the business’s stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $7.51, for a total transaction of $53,681.48. Following the completion of the transaction, the insider owned 1,373 shares in the company, valued at $10,311.23. The trade was a 83.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 23.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MASS. Nisa Investment Advisors LLC grew its holdings in 908 Devices by 453.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,784 shares of the company’s stock worth $27,000 after acquiring an additional 3,100 shares in the last quarter. Two Sigma Advisers LP acquired a new position in 908 Devices during the 4th quarter worth approximately $30,000. CWM LLC grew its holdings in 908 Devices by 541.2% during the 1st quarter. CWM LLC now owns 6,963 shares of the company’s stock worth $31,000 after acquiring an additional 5,877 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in 908 Devices during the 4th quarter worth approximately $36,000. Finally, Two Sigma Investments LP acquired a new position in 908 Devices during the 4th quarter worth approximately $42,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.